Patients listed for multi-organ transplants were excluded. All patients in our program are systematically informed about the option of LDLT. A potential LD was defined as an individual submitting a health questionnaire to our LD program. Unpaired t- and Chi-squared tests were used for group comparisons, as appropriate, and a p value < selleck kinase inhibitor 0.05 was regarded as statistically significant. Results: In 87% of all patients newly listed during the study period, a complete data set was available; these 491 patients form the basis of this analysis. 245 (50%) of these patients had at least one potential LD step forward. Demographic LT candidate factors significantly associated with a potential LD included younger

mean

age (52.2±0.7 vs. 54.4±0.7 years, p=0.03), Caucasian ethnicity (82% vs. 74%, p=0.02) and English mother tongue (77% vs. 65%, p<0.001). Female LT candidates were not statistically significantly more likely to have a potential LD step forward although a trend was observed (33% vs. 26%, p=0.06). As detailed in Table 1, Palbociclib liver disease etiology and more advanced liver impairment (MELD, Child-Pugh class) were also significantly associated with the presence of a LD. However, the presence of hepatoma, employment status, professional skill level, dependence on income support by the provincial disability program, and a history of recreational drug use or smoking did not differ in LT candidates with and without potential LD (data not shown). Conclusion: There are defined differences between

LT candidates with and without at least one potential LD. A better understanding of the factors 上海皓元医药股份有限公司 underlying these differences may help to improve access for all LT candidates to LDLT. Disclosures: Eberhard L. Renner – Advisory Committees or Review Panels: Vertex Canada, Novartis Canada, Novartis, Astellas Canada, Roche Canada, Gambroi; Speaking and Teaching: Novartis Canada, Astellas Canada, Roche Canada The following people have nothing to disclose: Rania N. Rabie, Arastoo Mokhtari, Mark Cattral, Anand Ghanekar, David Grant, Paul Greig, Gary Levy, Leslie Lilly, Ian McGilvray, Markus Selzner, Nazia Selzner Background: We previously proposed expanded selection criteria for liver transplantation (LT) for hepatocellular carcinoma (HCC), the Kyoto criteria, involving a combination of tumor number ≤lO, maximal diameter of each tumor <5 cm, and serum des-gamma-carboxy prothrombin levels <400 mAU/mL, and we have used these criteria since January 2007. In the present study, the usefulness of the criteria was prospectively as well as retrospectively validated. Methods: Two hundred patients with HCC who underwent living donor LT (LDLT) at our institute between February 1999 and February 2012 were enrolled in this study. Overall survival and the recurrence rate were investigated in patients classified according to the Kyoto criteria and the Milan criteria.